Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

McGill University

$100,000.00

New understanding and targets from the human phosphatome: towards the treatment of castration-resistant prostate cancer.

FY 2016-17

Summary
Prostate cancer is the most common cancer in Canadian men. Initiation and progression of prostate cancer are complex events that are mainly induced by hormones such as androgens. For this reason, current therapies do focus on depriving androgen to tumours. This is the most effective strategy to reduce tumour burden and treat recurrent prostate cancer. Unfortunately, a significant number of patients will eventually develop cancers that spread beyond the prostate. These metastasis are independent of androgen stimulation and they represent the most lethal form of this disease. Thus, identification of new therapeutic targets is urgently needed to prevent prostate cancer progression towards an androgen independent state, and to treat advanced metastatic tumours. To achieve this goal, our efforts are focused on the study of a family of proteins named Protein Tyrosine Phosphatases (PTPs). In this proposal, we will initially focus on PTP1B, initially identified as playing an important role in diabetes/obesity, and more recently identified by our group as an important player in prostate cancer development in the context of obesity. In a second part , we will examine three closely related PTPs named PRL1, 2, 3. Elevated in most human cancer types, they induce the rise of intracellular magnesium levels to fuel the overactive metabolism of cancel cells. Finally, as we are aware of many other members of this family that are also present in prostate cancers, we aim to complete a search for other PTPs that are changed in expression in androgen-independent prostate cancer. We believe that some of these 107 members of the human phosphatome may synergize or either counteract prostate cancer oncogenes. This will allow us to complete our scanning of these enzymes and to use those that are increased in PCa, as biomarkers of prognostic or as new druggable targets in androgen-independent, therapy-resistant prostate cancers.
Program
Project Grant
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
366581
Name
Tremblay Michel L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
New understanding and targets from the human phosphatome: towards the treatment of castration-resistant prostate cancer.
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Animal Model Of Cancer; Cell Biology; Cell Signaling; Inhibitor; Prostate Cancer; Protein Tyrosine Phosphatase; Shrna And Crispr Screen; Therapeutics; Tissue Bank; Tumour Biology
Abstract
Prostate cancer is the most common cancer in Canadian men. Initiation and progression of prostate cancer are complex events that are mainly induced by hormones such as androgens. For this reason, current therapies do focus on depriving androgen to tumours. This is the most effective strategy to reduce tumour burden and treat recurrent prostate cancer. Unfortunately, a significant number of patients will eventually develop cancers that spread beyond the prostate. These metastasis are independent of androgen stimulation and they represent the most lethal form of this disease. Thus, identification of new therapeutic targets is urgently needed to prevent prostate cancer progression towards an androgen independent state, and to treat advanced metastatic tumours. To achieve this goal, our efforts are focused on the study of a family of proteins named Protein Tyrosine Phosphatases (PTPs). In this proposal, we will initially focus on PTP1B, initially identified as playing an important role in diabetes/obesity, and more recently identified by our group as an important player in prostate cancer development in the context of obesity. In a second part , we will examine three closely related PTPs named PRL1, 2, 3. Elevated in most human cancer types, they induce the rise of intracellular magnesium levels to fuel the overactive metabolism of cancel cells. Finally, as we are aware of many other members of this family that are also present in prostate cancers, we aim to complete a search for other PTPs that are changed in expression in androgen-independent prostate cancer. We believe that some of these 107 members of the human phosphatome may synergize or either counteract prostate cancer oncogenes. This will allow us to complete our scanning of these enzymes and to use those that are increased in PCa, as biomarkers of prognostic or as new druggable targets in androgen-independent, therapy-resistant prostate cancers.
Competitiondate
201611
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tremblay, Michel L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~